Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis
Key facts
- Who runs it
- PT. Prodia Stem Cell Indonesia
- Where
- Indonesia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 31 people enrolled
- Started
- 3 Aug 2020
- Ended
- 8 Dec 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
- Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
- Record updated
- 25 February 2026
Who can take part
- Age
- 55 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients aged 55-70 years
- Suffering from grade 2-3 OA was identified by two observers who differed accordingly Kellgren-Lawrence research scale
- Absence of local or general infections
- Haematological and biochemical analysis without significant changes being made cause contraindications
- Patients can understand the nature of the study
- Written informed consent is given to patients
Who cannot take part
- Articular injection of the knee by any drug during the previous 3 months
- Participate in any clinical trial or treatment 30 days before the study
- There are signs of infection or positive serology for HIV, hepatitis and syphilis
- There is a history of cancer both in the family and yourself and the value of the examination tumour marker exceeds normal limits
- There is a congenital disease that causes significant deformity of the knee can interfere with cell applications and interpret results
- Other conditions may, according to medical criteria, not support participation in this research
- Patients are not willing to obey the study protocol
- Patients are subordinates or low ranking members
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the efficacy of Umbilical Cord Mesenchymal Stem Cell and secretome between arthroscopy and without arthroscopy intervention in OA patients. This study has 4 arms namely Arthroscopy + Booster, Arthroscopy + Pre-conditioning, Non-Arthroscopy + Booster, Non-Arthroscopy + Pre-conditioning.
The 4 groups in the trial
- Arthroscopy + BoosterTreatment being tested
After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
Treatment: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Arthroscopy + Pre-ConditioningTreatment being tested
After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
Treatment: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
- Non Arthroscopy + BoosterTreatment being tested
Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.
Treatment: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Non Arthroscopy + Pre-ConditioningTreatment being tested
Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.
Treatment: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Innovative Osteoarthritis Therapy Using Combination of Mesenchymal Stem Cell (MSC) and Conditioned Medium (CM): A Comparative Study on Arthroscopy and Non-Arthroscopy
- Record updated
- 25 February 2026